Russia begins deliveries of Avifavir to Brazil through Axis Biotec

16 July 2020

GMP News

Chromis, a joint venture established by the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, announce the signing of license and collaboration agreement with Brazil’s Axis BioTec to deliver the first Russian anti-COVID drug Avifavir to Brazil.

Under the agreement Chromis will deliver at least 100,000 packs of Avifavir to Brazil until the end of 2020 with at least 200,000 packs set to be delivered in 2021.

Avifavir has demonstrated efficacy in clinical trials held in 35 medical centers across Russia involving 330 patients with confirmed COVID-19. The drug disrupts the reproduction mechanisms of the coronavirus, relieving symptoms and halving the treatment period compared to standard therapy.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“RDIF and ChemRar have begun to fully explore Avifavir’s export potential, which is in high demand not only from partner states in CIS, but beyond. Latin America, and Brazil in particular, are now experiencing difficulties due to the spread of coronavirus, and our drug will allow for the effective treatment of patients and a reduced burden on medical facilities. We are ready to meet the growing foreign demand for Avifavir and are open to further international partnerships”.

Eduardo Cruz, Director of Silvestre Labs said:

“Axis BioTec, represented by Silvestre Labs, is honored to be the first pharmaceutical company in Brazil to access this product and to bring this drug to the country. We are excited that our doctors will soon have such a promising and effective drug which will help save thousands of lives, as we are currently the country with the second highest number of coronavirus deaths in the world”.




Read more


Read more

Media Center

Read more